顺铂和奈达铂同步放疗治疗鼻咽癌的近期疗效及毒副作用比较

Comparison of the Short-term Efficacy and Adverse Effects between Nedaplatin and Cisplatinumcis plus Concurrent Radiotherapy for Advanced Nasopharyngeal Carcinoma

目的：探讨奈达铂和顺铂同步放疗治疗鼻咽癌的近期疗效及毒副作用。方法选取2008年1月-2013年1月在我院首次行放射治疗的102例局部晚期鼻咽癌患者，随机分为顺铂同步化疗组（A组，n=50）与奈达铂同步化疗组（B组，n=52）。A组给予顺铂同步化疗，B组给予奈达铂同步化疗，比较两组患者的近期疗效（原发灶及颈部淋巴结退缩情况）及毒副反应的发生情况。结果同步放化疗后，两组的原发灶及颈部淋巴结退缩总有效率比较，差异均无统计学意义（P〉0.05）；B组患者呕吐及口腔黏膜反应的发生率均较A组明显降低，差异具有统计学意义（P〈0.05）。结论奈达铂与顺铂同步放疗治疗鼻咽癌的临床疗效相当，但奈达铂的安全性更高。

Objective To investigate the short-term efficacy and adverse effects of nedaplatin or cisplatinumcis plus concurrent radiotherapy in the treatment of advanced nasopharyngeal carcinoma. Methods A total of 102 patients with local advanced nasopharyngeal carcinoma admitted in our hospital for the first radiotherapy between January 2008 and January 2013 were selected and randomly divided into two groups. Group A （n=50） was given venous 80 mg＆#183;m-2 cisplatinumcis every 22-28 days, and group B （n=52） received Nedaplatin by 80 mg＆#183;m-2 via intravenous infusion every 22-28 days, all in the conventional radiotherapy duration. The regression of primary lesion and cervical lymph node and incidence of adverse re-actions after treatment were compared between the two groups. Results After concurrent chemoradiotherapy, no significant difference was found in the efficacy of regression of primary lesion and cervical lymph node （P〉0.05）. The incidence rates of vomiting and oral mucosa reaction of group B were significantly lower than those of group A（P〉0.05）. Conclusion The ef-ficacy of nedaplatin plus concurrent radiotherapy in the treatment of advanced nasopharyngeal carcinoma was equal to that of cisplatinumcis plus concurrent radiotherapy, but nedaplatin was much safer.